Thalidomide BMS (previously Thalidomide Celgene) Uniunea Europeană - română - EMA (European Medicines Agency)

thalidomide bms (previously thalidomide celgene)

bristol-myers squibb pharma eeig - thalidomide - mielom multiplu - imunosupresoare - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Vidaza Uniunea Europeană - română - EMA (European Medicines Agency)

vidaza

bristol-myers squibb pharma eeig - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Reblozyl Uniunea Europeană - română - EMA (European Medicines Agency)

reblozyl

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - alte preparate antianemice - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

Onureg Uniunea Europeană - română - EMA (European Medicines Agency)

onureg

bristol-myers squibb pharma eeig - azacitidină - leucemie, mieloidă, acută - agenți antineoplazici - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Breyanzi Uniunea Europeană - română - EMA (European Medicines Agency)

breyanzi

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agenți antineoplazici - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Opdualag Uniunea Europeană - română - EMA (European Medicines Agency)

opdualag

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanomul - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Sotyktu Uniunea Europeană - română - EMA (European Medicines Agency)

sotyktu

bristol-myers squibb pharma eeig - deucravacitinib - psoriazis - imunosupresoare - treatment of moderate-to-severe plaque psoriasis in adults.

SPRANTIFEN 25 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sprantifen 25 mg

abiogen pharma s.p.a. - italia - ketoprofenum - compr. film. - 25mg - antiinflamatoare si antireumatice nesteroidiene derivati de acid propionic

GLETOR 10 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

gletor 10 mg

glenmark pharmaceuticals s.r.o. - atorvastatinum - compr. film. - 10mg - hipocolesterolemiante si hipotrigliceridemiante inhibitori ai hmg coa reductazei

GLETOR 20 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

gletor 20 mg

glenmark pharmaceuticals s.r.o. - atorvastatinum - compr. film. - 20mg - hipocolesterolemiante si hipotrigliceridemiante inhibitori ai hmg coa reductazei